ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for alerts Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Appili Therapeutics Inc

Appili Therapeutics Inc (APLI)

0,04
0,005
( 14,29% )
Aktualisiert: 15:30:02

Ihr Hub für Echtzeit-Streaming-Zitate, Ideen und Live-Diskussionen

Wichtige Statistiken und Details

Current Price
0,04
Gebot
0,035
Fragen
0,04
Volumen
1.251
0,04 Tagesbereich 0,04
0,025 52-Wochen-Bereich 0,06
Marktkapitalisierung
Handelsende
0,035
Handelsbeginn
0,04
Letzte Trade
250
@
0.04
Letzter Handelszeitpunkt
15:30:02
Finanzvolumen
-
VWAP
-
Durchschnittliches Volumen (3 Mio.)
75.876
Ausgegebene Aktien
121.266.000
Dividendenrendite
-
Kurs-Gewinn-Verhältnis
-0,96
Gewinn pro Aktie (EPS)
-0,03
Erlöse
6,69M
Nettogewinn
-3,78M

Über Appili Therapeutics Inc

Sektor
Pharmaceutical Preparations
Branche
Pharmaceutical Preparations
Hauptsitz
Halifax, Nova Scotia, Can
Gegründet
-
Appili Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Börse with ticker APLI. The last closing price for Appili Therapeutics was $0,04. Over the last year, Appili Therapeutics shares have traded in a share price range of $ 0,025 to $ 0,06.

Appili Therapeutics currently has 121.266.000 shares in issue. The market capitalisation of Appili Therapeutics is $4,24 million. Appili Therapeutics has a price to earnings ratio (PE ratio) of -0.96.

APLI Neueste Nachrichten

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A...

Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives

Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a social innovation platform dedicated to accelerating promising health innovations, today announced the appointment of Sylvia Hermina to...

Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the achievement of a key milestone...

Appili Therapeutics Presents Update on ATI-1701 Biodefense Vaccine Candidate at IDWeek™ 2024

ATI-1701 provides full protection against lethal tularemia in animal models after one year Company to provide update on tularemia vaccine candidate ATI-1701 and present new data on efficacy...

Appili Therapeutics – Press Release Correction

HALIFAX, Nova Scotia, Oct. 10, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX:APLI; OTCPink: APLIF) (the “Company” or “Appili”), announces correction to its press release entitled...

Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval

Appili has a commercial-stage pipeline, has raised CAD $100M towards developing therapeutics for the global infectious disease and biodefense markets, and subject to the renewal of certain...

Appili Therapeutics Announces Mailing of the Management Information Circular in Connection with the Special Meeting of Shareholders

Your vote is important no matter how many votes you hold.Shareholders who have questions or need assistance with voting their shares should contact info@appilitherapeutics.com HALIFAX, Nova...

Aditxt Delivers Shareholder Update and 2024 Year-End Plan

Acquisition target Evofem reported revenue of $7.8 million for the six months ended June 30, 2024 Acquisition target Appili has received approximately $6.0 million of the total $14.0 million to...

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
10.00514.28571428570.0350.040.0351589080.035CS
40.015600.0250.0450.0251159220.03438458CS
120.00514.28571428570.0350.0450.025758760.03277537CS
260.00514.28571428570.0350.050.025926370.03610099CS
520.00514.28571428570.0350.060.0251214520.03736174CS
156-0.74-94.87179487180.780.780.0251843400.087322CS
260-1.09-96.46017699121.131.60.0251653580.2761566CS
  • Volumen
  • % Tops
  • % Flops
SymbolPreisVol.
FLNTFlint Corporation
$ 0,03
(50,00%)
675k
SFDNXT Energy Solutions Inc
$ 0,25
(42,86%)
101,5k
CVOCoveo Solutions Inc
$ 7,21
(21,18%)
914,6k
NUMINuminus Wellness Inc
$ 0,03
(20,00%)
134,03k
RVXResverlogix Corp
$ 0,065
(18,18%)
60,9k
AXISAxis Auto Finance Inc
$ 0,005
(-50,00%)
501k
SMCSulliden Mining Capital Inc
$ 0,02
(-20,00%)
578,24k
BKIBlack Iron Inc
$ 0,045
(-18,18%)
178,3k
WJXWajax Corporation
$ 20,59
(-17,28%)
384,16k
KRNKarnalyte Resources Inc
$ 0,12
(-14,29%)
11k
TWMTidewater Midstream and Infrastructure Ltd
$ 0,225
(-11,76%)
5,42M
ACAir Canada
$ 22,19
(2,07%)
3,92M
BTEBaytex Energy Corp
$ 4,30
(0,70%)
3,6M
VRNVeren Inc
$ 7,30
(2,10%)
2,78M
TVETamarack Valley Energy Ltd
$ 4,43
(0,23%)
2,74M
Keine Diskussionen Gefunden.
Neuen Thread Erstellen

Kürzlich von Ihnen besucht

Delayed Upgrade Clock